TN-R3

Overview

TN-R3 is a synthetic peptide designed to act on three receptors the body uses to regulate blood sugar, appetite, and energy use. Two of them, the GLP-1 and GIP receptors, respond to hormones the gut releases after a meal, a group known as incretins. The third, the glucagon receptor, is involved in how the body expends and mobilizes stored energy. Acting on all three at once is what distinguishes TN-R3 from most peptides in this class, which engage only one or two, and it places the compound among the most closely studied designs in current metabolic research. The interest comes from the idea that combining pathways may do something that engaging any one of them alone does not.

How it works

After eating, the intestine releases the incretin hormones GLP-1 and GIP, which signal the body to release insulin in proportion to blood sugar, so the response is matched to need. The three receptors TN-R3 targets belong to the same family of cell surface receptors and rely on a shared internal messenger called cyclic AMP to carry their signal into the cell. By engaging the two incretin receptors alongside the glucagon receptor, TN-R3 is built to influence several metabolic pathways at the same time rather than a single one. Researchers study this multi receptor design to understand how the signals add together or interact once they are inside the cell.

What researchers study

The GLP-1 receptor is studied for steadying blood sugar, slowing the rate at which the stomach empties, and reducing appetite through signals in the brain. The GIP receptor is examined for its part in insulin release and in how fat tissue stores energy. The glucagon receptor is studied largely in the liver, where it is associated with energy expenditure and lipid processing, though its effect on energy use beyond animal models is still being defined. The central question across this research is how the three pathways behave together, and what combined activation accomplishes that no single pathway does on its own. Much of the foundational work sits in animal and early stage models, in a field that is moving quickly.

Published references

• GLP-1, GIP and Glucagon Receptor Poly-agonists: A New Era in Obesity Pharmacotherapy.
• Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor.
• The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health.

Research Use Only. Not for human or animal use.